Lifestyle Counseling, mHealth Interventions Show Promise for Slowing CKD Progression

Chronic kidney disease (CKD) continues to represent a growing burden on health systems worldwide, and abstracts presented at the World Congress of Nephrology 2026 in Yokohama, Japan, suggest that structured counseling and mobile health (mHealth) platforms may offer meaningful tools for slowing disease progression and, in some cases, preventing it.^1,2

Multidisciplinary Counseling Slows eGFR Decline in Japanese Patients With CKD

A retrospective, single-center study conducted at Osaka Keisatsu Hospital evaluated the impact of comprehensive lifestyle and nutritional counseling on 51 outpatients with CKD (mean age, 69 years; median estimated glomerular filtration rate [eGFR], 22.4 mL/min/1.73 m²). Researchers tracked changes in eGFR slope before and after patients enrolled in a multidisciplinary counseling program.¹

The results were clinically meaningful. Before counseling, patients experienced a mean annual decline in eGFR of –3.67 mL/min/1.73 m² (95% CI, –9.45 to –1.44). Following the intervention, that rate of decline slowed to –2.15 mL/min/1.73 m² (95% CI, –4.71 to 0.09) per year, a statistically significant improvement (P = .024).¹

Beyond renal function, the counseling program appeared to drive measurable behavioral change. The rate of home blood pressure monitoring implementation increased from 70.6% before counseling to 94.1% after counseling, a statistically significant shift (P = .003). Medication parameters, including use of renin-angiotensin system inhibitors and sodium-glucose transport protein 2 inhibitors, remained largely stable across the study period.¹

"Comprehensive counseling may contribute to slowing renal function decline by facilitating patient engagement in self-management," the researchers concluded.¹

For pharmacists, the findings reinforce the value of patient education and behavioral support as complements to pharmacotherapy in CKD management. Although medication optimization remains central to nephrology care, this study suggests that helping patients understand and actively participate in monitoring their own health—through consistent blood pressure tracking and lifestyle modification—may yield measurable renal benefits over time.

mHealth Intervention Reduces CKD Incidence in Older Vietnamese Adults

A separate randomized controlled trial out of Vietnam took a prevention-focused lens, examining whether a structured mHealth program could reduce the incidence of new-onset CKD in older community-dwelling adults.²

Researchers enrolled 702 participants 60 years and older with preserved kidney function (eGFR of 60 mL/min/1.73 m² or higher), randomly assigning them 1:1 to either a 12-month mHealth intervention or a control group receiving standard educational pamphlets. The intervention consisted of weekly educational text messages and monthly coaching calls, a low-infrastructure model designed with scalability in mind.²

At the end of the trial period, new-onset CKD—defined as eGFR falling below 60 mL/min/1.73 m² and confirmed after at least 90 days—occurred in approximately 8.5% of intervention participants compared to 11.1% of controls. The mHealth program reduced the risk of developing CKD by a statistically significant margin (HR, 0.76; 95% CI, 0.59-0.97; P = .03). The intervention group also experienced a slower mean annual eGFR decline compared with controls (–1.2 vs –2.1 mL/min/1.73 m²; P = .04).²

One notable finding emerged in subgroup analysis: the benefit on CKD incidence was concentrated among participants without type 2 diabetes (T2D), with a significant interaction effect (P-interaction = .02). Among participants with T2D, the intervention did not demonstrate a statistically significant reduction in CKD incidence (HR, 0.94; 95% CI, 0.67-1.32), although the researchers noted this may reflect limited statistical power in that subgroup rather than a true absence of effect.²

The authors emphasized the model’s scalability, particularly in lower-middle-income settings where nephrology infrastructure is limited. Weekly messaging and monthly coaching require no novel diagnostics or medications and can be deployed within existing primary care networks, in contrast to pharmacological approaches that face access and prescribing barriers in resource-constrained environments.²

That said, the researchers cautioned that generalizability has limits: Participants were community-dwelling, digitally accessible, and excluded those with severe baseline kidney impairment. Formal cost-effectiveness analyses and implementation studies will be needed before the findings can inform broader population-level CKD policy.²

Implications for Pharmacy Practice

Taken together, these studies point toward a consistent theme: structured, nonpharmacological interventions—whether delivered in a clinic counseling room or via a patient's smartphone—can produce meaningful improvements in CKD trajectories.

For pharmacists practicing in ambulatory care, nephrology, or community settings, both findings carry practical relevance. Medication therapy management visits represent an opportunity to reinforce the kind of self-monitoring behaviors, like blood pressure tracking, dietary awareness, and medication adherence, that the Osaka study suggests are amenable to improvement through education. Meanwhile, the Vietnamese trial's mHealth model aligns closely with the expanding role of digital health tools in pharmacy-driven chronic disease management.^1,2

As CKD prevalence continues to rise globally, interventions that empower patients and extend the reach of clinical guidance beyond the clinic visit may prove to be essential components of comprehensive kidney care.

REFERENCES

1. Tatsumi R, Oka K, Tanoue H, et al. Effectiveness of comprehensive lifestyle and nutritional counseling for outpatients with chronic kidney disease. Presented at: World Congress of Nephrology 2026; March 28-31, 2026; Yokohama, Japan. Abstract ID: WCN26-AB-7378. Accessed via online platform on April 24, 2026.

2. Tung PT, Minh DG, Minh NT. Effectiveness of a mobile health (mHealth) intervention on the prevention of chronic kidney disease in older adults: a randomized controlled trial in Vietnam. Presented at: World Congress of Nephrology 2026; March 28-31, 2026; Yokohama, Japan. Abstract ID: WCN26-AB-1242. Accessed via online platform on April 24, 2026.